CD309 (VEGFR-2/KDR) ( #130-093-598 #130-095-324 #130-093-601 #130-093-603 )

CD309 (VEGFR-2/KDR)

Overview

The CD309 (VEGFR-2/KDR) antibodies are suitable to identify and enumerate human, mouse or rat CD309⁺ cells by flow cytometry or immunohistochemistry.

For the enrichment of endothelial progenitor cells (EPCs) and subsequent enumeration by flow cytometry, based on the expression of CD133, CD34, and CD309 (VEGFR-2/KDR), please refer to the EPC Enrichment and Enumeration Kit.

Details

Background information
The CD309 antibody recognizes the CD309 antigen, a transmembrane tyrosine kinase, and is also known as vascular endothelial growth factor receptor-2 (VEGFR-2) and kinase insert domain–containing receptor (KDR). CD309 is a high-affinity receptor for VEGF and plays a role in hematopoiesis. It is also involved in angiogenesis, both during embryogenesis and in the context of homeostatic or pathological events, e.g., vascularization of tumors. It has been identified on a subset of hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs) as well as on their common progenitor, the hemangioblast.^1–3 CD309 expression is also found on mature endothelial cells (ECs).⁴

Clone	Isotype
ES8-20E6	Mouse IgG1

Figure 1

Human PBMCs were spiked with human umbilical vein endothelial cells (HUVECs), stained with CD309 (VEGFR-2/KDR) antibodies conjugated to PE (A) or APC (B) as well as with CD45-FITC, and analyzed by flow cytometry using the MACSQuant® Analyzer. Cells labeled with CD309 (VEGFR-2/KDR)-Biotin (C) were stained with Anti-Biotin-APC as well as CD45-FITC.